MA32812B1 - Composition pharmaceutique d'un inhibiteur puissant du vhc pour une administration orale - Google Patents

Composition pharmaceutique d'un inhibiteur puissant du vhc pour une administration orale

Info

Publication number
MA32812B1
MA32812B1 MA33867A MA33867A MA32812B1 MA 32812 B1 MA32812 B1 MA 32812B1 MA 33867 A MA33867 A MA 33867A MA 33867 A MA33867 A MA 33867A MA 32812 B1 MA32812 B1 MA 32812B1
Authority
MA
Morocco
Prior art keywords
pharmaceutical composition
oral
vhc
powerful antagonist
antagonist
Prior art date
Application number
MA33867A
Other languages
Arabic (ar)
English (en)
Inventor
Feng-Jing Chen
Juan Francisco Gel
Maria Fernanda Villagra
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41650279&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA32812(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of MA32812B1 publication Critical patent/MA32812B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dispersion Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

L'invention porte sur une composition pharmaceutique du composé suivant (1), un puissant inhibiteur du virus de l'hépatite C (VHC), ou sur un sel pharmaceutiquement acceptable de celui-ci, pour une administration orale.
MA33867A 2008-11-21 2011-05-20 Composition pharmaceutique d'un inhibiteur puissant du vhc pour une administration orale MA32812B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11678908P 2008-11-21 2008-11-21
PCT/US2009/064908 WO2010059667A1 (fr) 2008-11-21 2009-11-18 Composition pharmaceutique d'un inhibiteur puissant du vhc pour une administration orale

Publications (1)

Publication Number Publication Date
MA32812B1 true MA32812B1 (fr) 2011-11-01

Family

ID=41650279

Family Applications (1)

Application Number Title Priority Date Filing Date
MA33867A MA32812B1 (fr) 2008-11-21 2011-05-20 Composition pharmaceutique d'un inhibiteur puissant du vhc pour une administration orale

Country Status (35)

Country Link
US (2) US20120101049A1 (fr)
EP (1) EP2358355B1 (fr)
JP (1) JP5553839B2 (fr)
KR (1) KR20110087297A (fr)
CN (1) CN102223875A (fr)
AR (1) AR074391A1 (fr)
AU (1) AU2009316755B2 (fr)
BR (1) BRPI0921070A2 (fr)
CA (1) CA2738732A1 (fr)
CL (1) CL2011000878A1 (fr)
CO (1) CO6361900A2 (fr)
CY (1) CY1114892T1 (fr)
DK (1) DK2358355T3 (fr)
EA (1) EA022272B1 (fr)
EC (1) ECSP11011065A (fr)
ES (1) ES2445516T3 (fr)
HR (1) HRP20140097T1 (fr)
IL (1) IL211832A (fr)
MA (1) MA32812B1 (fr)
ME (1) ME01614B (fr)
MX (1) MX2011005151A (fr)
MY (1) MY155402A (fr)
NZ (1) NZ592383A (fr)
PE (1) PE20120032A1 (fr)
PL (1) PL2358355T3 (fr)
PT (1) PT2358355E (fr)
RS (1) RS53121B (fr)
SG (1) SG171771A1 (fr)
SI (1) SI2358355T1 (fr)
TN (1) TN2011000258A1 (fr)
TW (1) TWI469801B (fr)
UA (1) UA105777C2 (fr)
UY (1) UY32252A (fr)
WO (1) WO2010059667A1 (fr)
ZA (1) ZA201102029B (fr)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UY32099A (es) 2008-09-11 2010-04-30 Enanta Pharm Inc Inhibidores macrocíclicos de serina proteasas de hepatitis c
PE20120322A1 (es) * 2009-07-07 2012-04-14 Boehringer Ingelheim Int Composicion farmaceutica que comprende faldaprevir o una sal del mismo en un vehiculo auto-emulsionante
WO2012041771A1 (fr) 2010-09-30 2012-04-05 Boehringer Ingelheim International Gmbh Thérapie combinée pour le traitement d'une infection par le vhc
CN103179966B (zh) * 2010-10-08 2017-03-15 诺瓦提斯公司 磺酰胺ns3抑制剂的维生素e制剂
KR20140003521A (ko) 2010-12-30 2014-01-09 이난타 파마슈티칼스, 인코포레이티드 페난트리딘 매크로사이클릭 ｃ형 간염 세린 프로테아제 억제제
CN103534256B (zh) 2010-12-30 2016-08-10 益安药业 大环丙型肝炎丝氨酸蛋白酶抑制剂
US10201584B1 (en) 2011-05-17 2019-02-12 Abbvie Inc. Compositions and methods for treating HCV
US8492386B2 (en) 2011-10-21 2013-07-23 Abbvie Inc. Methods for treating HCV
US8466159B2 (en) 2011-10-21 2013-06-18 Abbvie Inc. Methods for treating HCV
CN104023726A (zh) 2011-10-21 2014-09-03 艾伯维公司 用于治疗hcv的一种或多种daa的联合治疗(例如，与abt-072或abt-333)
DE112012003510T5 (de) 2011-10-21 2015-03-19 Abbvie Inc. Verfahren zur Behandlung von HCV umfassend mindestens zwei direkt wirkende antivirale Wirkstoffe, Ribavirin aber nicht Interferon
US20140037719A1 (en) 2012-01-12 2014-02-06 Boehringer Ingelheim International Gmbh Stabilized pharmaceutical formulations of a potent hcv inhibitor
JP2015509980A (ja) 2012-03-14 2015-04-02 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｈｃｖ−ｈｉｖ同時感染患者集団のｈｃｖ感染症を治療するための併用療法
WO2013147749A1 (fr) 2012-03-27 2013-10-03 Boehringer Ingelheim International Gmbh Polythérapie orale pour le traitement d'une infection au vhc dans des populations de sous-génotypes de patients spécifiques
WO2013147750A1 (fr) 2012-03-27 2013-10-03 Boehringer Ingelheim International Gmbh Polythérapie orale pour le traitement d'une infection au vhc dans une sous-population de patients spécifiques
WO2013143581A1 (fr) 2012-03-28 2013-10-03 Boehringer Ingelheim International Gmbh Polythérapie pour le traitement d'une infection par le vhc dans une sous-population de sous-génotype de patients spécifique
ES2673870T3 (es) * 2012-05-07 2018-06-26 Bristol-Myers Squibb Holdings Ireland Formulación de dosificación oral sólida de [(1S)-1-{[(2S,4R)-4-(7-cloro-4-metoxiisoquinolin-1-iloxi)-2-({(1R,2S)-1-[(ciclopropilsulfonil) carbamoil]-2-etenilciclopropil} carbamoil) pirrolidin-1-il] carbonil}-2,2-dimetil-propil] carbamato de 1,1-dimetiletilo
UA119315C2 (uk) 2012-07-03 2019-06-10 Гіліад Фармассет Елелсі Інгібітори вірусу гепатиту с
WO2014138374A1 (fr) 2013-03-08 2014-09-12 Boehringer Ingelheim International Gmbh Polythérapie par voie orale pour le traitement d'une infection par le vhc chez une sous-population spécifique de patients
JP6511432B2 (ja) 2013-03-15 2019-05-15 ギリアード サイエンシーズ， インコーポレイテッド Ｃ型肝炎ウイルスの大環状二環式阻害剤
WO2015103490A1 (fr) 2014-01-03 2015-07-09 Abbvie, Inc. Formes galéniques antivirales solides
WO2017062840A1 (fr) * 2015-10-09 2017-04-13 Trek Therapeutics, Pbc Thérapie combinatoire pour le traitement du virus de l'hépatite c
JP7129703B2 (ja) 2016-04-28 2022-09-02 エモリー ユニバーシティー アルキン含有ヌクレオチド及びヌクレオシド治療組成物並びにそれらに関連した使用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6323180B1 (en) * 1998-08-10 2001-11-27 Boehringer Ingelheim (Canada) Ltd Hepatitis C inhibitor tri-peptides
GB0008785D0 (en) * 2000-04-10 2000-05-31 Novartis Ag Organic compounds
CA2466851C (fr) * 2001-11-26 2012-09-11 Supergen, Inc. Procede de preparation et d'utilisation d'huile de ricin polyoxyethylee dans des compositions pharmaceutiques
CZ294371B6 (cs) * 2002-06-10 2004-12-15 Pliva - Lachema, A. S. Stabilizovaná farmaceutická kompozice na bázi polyoxyethylovaného ricinového oleje a způsob její přípravy
CL2004001161A1 (es) 2003-05-21 2005-04-08 Boehringer Ingelheim Int Compuestos describe compuestos derivados de quinolina; composicion farmaceutica; y su uso para tratar una enfermedad causada por el virus de la hepatitis c.
EP1753775B1 (fr) * 2004-05-25 2012-12-26 Boehringer Ingelheim International GmbH Processus de preparation d'inhibiteurs de protease hcv acyclique

Also Published As

Publication number Publication date
BRPI0921070A2 (pt) 2019-09-24
EA201100795A1 (ru) 2012-01-30
ES2445516T3 (es) 2014-03-03
US20120101049A1 (en) 2012-04-26
DK2358355T3 (da) 2013-12-16
US20150038532A1 (en) 2015-02-05
ME01614B (me) 2014-09-20
IL211832A (en) 2015-02-26
CA2738732A1 (fr) 2010-05-27
CL2011000878A1 (es) 2011-09-02
EP2358355B1 (fr) 2013-11-06
PT2358355E (pt) 2014-01-08
JP5553839B2 (ja) 2014-07-16
CY1114892T1 (el) 2016-12-14
JP2012509336A (ja) 2012-04-19
KR20110087297A (ko) 2011-08-02
UY32252A (es) 2010-06-30
CN102223875A (zh) 2011-10-19
TN2011000258A1 (en) 2012-12-17
ZA201102029B (en) 2011-11-30
EA022272B1 (ru) 2015-12-30
RS53121B (sr) 2014-06-30
IL211832A0 (en) 2011-06-30
AU2009316755A1 (en) 2010-05-27
NZ592383A (en) 2012-11-30
CO6361900A2 (es) 2012-01-20
MY155402A (en) 2015-10-15
TW201023859A (en) 2010-07-01
PL2358355T3 (pl) 2014-04-30
TWI469801B (zh) 2015-01-21
AR074391A1 (es) 2011-01-12
PE20120032A1 (es) 2012-02-12
SI2358355T1 (sl) 2014-02-28
EP2358355A1 (fr) 2011-08-24
HRP20140097T1 (hr) 2014-03-14
AU2009316755B2 (en) 2015-10-08
SG171771A1 (en) 2011-07-28
WO2010059667A1 (fr) 2010-05-27
MX2011005151A (es) 2011-05-30
UA105777C2 (uk) 2014-06-25
ECSP11011065A (es) 2011-06-30

Similar Documents

Publication Publication Date Title
CY1114892T1 (el) Φαρμακευτικη συνθεση ενος ισχυρου αναστολεα του hcv για απο του στοματος χορηγηση
EA200970585A1 (ru) Бензамидные производные как агонисты ер-рецепторов
CY1119261T1 (el) Παραγωγα θειαζολιου
NO20072978L (no) Nye betuinderivater, preparat derav og anvendelse derav
EA201101398A1 (ru) Замещенные пиперидины в качестве антагонистов ccr3
PT2310356E (pt) Derivados de adamantildiamida e a sua utilização
EA201101672A1 (ru) Замещенные производные аминомасляной кислоты в качестве ингибиторов неприлизина
EA200870193A1 (ru) Цитотоксические агенты, включающие новые производные томаймицина, и их терапевтическое применение
EA201101026A1 (ru) Ингибиторы бета-секретазы
EA201070786A1 (ru) Бензофуропиримидиноны
TW200728307A (en) Novel spirochromanone derivatives
SE0400284D0 (sv) Novel compounds
WO2010033444A8 (fr) Formes cristallines d'un dérivé 2-thiazolyl-4-quinolinyl-oxy, un inhibiteur puissant du vhc
TW200630344A (en) Tetracyclic indole derivatives as antiviral agents
EA201001724A1 (ru) Производные изоксазола и их применение в качестве потенциирующих средств для метаботропных глутаматных рецепторов
WO2007029029A3 (fr) Derives d'indole tetracycliques utilises comme agents antiviraux
CY1113395T1 (el) Σταθερη φαρμακευτικη συνθεση που περιεχει πυριμιδινη-σουλφαμιδη
WO2006082523A3 (fr) Compositions pharmaceutiques de metformine
TW200833370A (en) Pharmaceutical composition containing low substituted hydroxypropylcellulose
NO20043367L (no) Oralt farmasoytisk preparat
EA200870302A1 (ru) 1,3-диоксанкарбоновые кислоты
ATE554084T1 (de) N-hydroxyacrylamidverbindungen
CY1122182T1 (el) Ανοσοκατασταλτικες φαρμακοτεχνικες μορφες
UA97348C2 (en) HETEROCYCLIC NF-kB INHIBITORS
ATE399156T1 (de) Neue indol- oder benzimidazol-derivate